Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

Next Previous
Search
Trial Profile

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon; Retifanlimab
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASTRO-VAC CNS; BRIA-ABC
  • Sponsors BriaCell Therapeutics Corp

Most Recent Events

  • 30 Apr 2025 According to a BriaCell Therapeutics Corp media release, data from the study were presented at AACR 2025
  • 30 Apr 2025 Results presented in the BriaCell Therapeutics Media Release
  • 23 Apr 2025 According to a BriaCell Therapeutics Corp media release, company will present data from this study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 at McCormick Place, Chicago, IL.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top